Harmony Biosciences Holdings, Inc. $HRMY Stake Lowered by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 1.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 466,072 shares of the company’s stock after selling 5,956 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.81% of Harmony Biosciences worth $15,469,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in HRMY. Financial Management Professionals Inc. bought a new position in shares of Harmony Biosciences during the first quarter valued at approximately $29,000. GF Fund Management CO. LTD. bought a new position in Harmony Biosciences in the 4th quarter worth approximately $41,000. CWM LLC grew its holdings in Harmony Biosciences by 34.8% in the 1st quarter. CWM LLC now owns 2,704 shares of the company’s stock worth $90,000 after buying an additional 698 shares in the last quarter. GAMMA Investing LLC grew its holdings in Harmony Biosciences by 222.9% in the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company’s stock worth $97,000 after buying an additional 2,022 shares in the last quarter. Finally, Virtus Investment Advisers Inc. bought a new position in Harmony Biosciences in the 4th quarter worth approximately $124,000. 86.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

HRMY has been the subject of a number of recent analyst reports. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. UBS Group decreased their price objective on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a report on Monday, April 28th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $55.00 price objective (up from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. Oppenheimer initiated coverage on Harmony Biosciences in a report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 price objective for the company. Finally, Mizuho increased their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Harmony Biosciences presently has an average rating of “Buy” and an average price target of $51.00.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY opened at $37.86 on Friday. The stock has a fifty day moving average price of $34.47 and a two-hundred day moving average price of $33.69. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. The firm has a market cap of $2.18 billion, a P/E ratio of 12.21, a PEG ratio of 0.44 and a beta of 0.84. Harmony Biosciences Holdings, Inc. has a 1 year low of $26.47 and a 1 year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.10). The firm had revenue of $200.49 million for the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.